MSPrecise, a cerebrospinal fluid test to diagnose relapsing-remitting multiple sclerosis (RRMS), displays high accuracy rate in identifying RRMS patients, a study reports.
Investigators tested cerebrospinal fluid pellets from patients with RRMS and other neurological diseases for the presence RRMS-enriched mutation patterns and found:
• 75% sensitivity in RRMS patients
• 88% specificity in other neurological diseases
• 84% accuracy for identifying RRMS patients or patients who will develop RRMS
Citation: Rounds WH, Salinas EA, Wilks TB 2nd, et al. MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing. Gene. 2015. pii: S0378-1119(15)00821-5. doi: 10.1016/j.gene.2015.07.011.